CyGene Laboratories Launches DNA Analysis to Identify Stroke, Fabry Disease

 

July 22, 2008

July 22, 2008 - CyGene Laboratories Inc. this week is introducing StrokeScan, a genetic screening test aimed at identifying high risk individuals who have a family history of stroke, cardiovascular or kidney disease.

StrokeScan analyzes genes that have been associated with the increased risk of stroke and the “alpha-galactosidase A” gene that is responsible for Fabry disease. Fabry disease is a genetic disorder that results in an enzyme deficiency that commonly causes death before age 55 by way of stroke, heart attack or kidney failure. Fabry disease was originally thought to occur in only one in 50,000 people. New scientific evidence, based on newborn screening, suggests that it may be more than 10 times more common as previously believed, and to occur in one in 3,500 people. Simple biochemical tests currently used to diagnose Fabry miss more than 70 percent of women and 15 percent of men who have the disease. The average time to arrive at a medical diagnosis after the onset of symptoms can take more than 10 years, CyGene said.

Each test costs about $500, the company said.

For more information: www.CyGeneDirect.com